Literature DB >> 16369311

Escitalopram in adolescent major depression.

James L Schaller1, David B Rawlings.   

Abstract

Escitalopram is the purified functional isomer contained in citalopram. Escitalopram is now prescribed in 26 countries. In the United States, the only US Food and Drug Administration (FDA)-approved selective serotonin reuptake inhibiter (SSRI) for adolescents is fluoxetine. However, in clinical practice all antidepressants are used in adolescents. Five patients had parents who opted for the use of escitalopram instead of other treatments. Reasons included poor response and side effects from other SSRIs. Specifically, escitalopram was considered possibly less likely to cause obesity than paroxetine. It also caused a lower frequency of akathisia than fluoxetine, more stable blood levels over years than sertraline, very low drug interactions, and a low onset of anxiety if using a 5-mg starting dose. Although studies in adolescents are very limited for escitalopram, its parent medication--citalopram--has been used in over 40 million patients. Parents and adolescent patients should be made aware of all antidepressant options, if psychopharmacology is indicated. In some patients, escitalopram may have use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16369311      PMCID: PMC1681392     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  9 in total

1.  Brief report: citalopram in child and adolescent depression with anxiety.

Authors:  J L Schaller; D Behar
Journal:  MedGenMed       Date:  2001-10-31

Review 2.  Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.

Authors:  D J Greenblatt; L L von Moltke; J S Harmatz; R I Shader
Journal:  J Clin Psychopharmacol       Date:  1999-10       Impact factor: 3.153

Review 3.  Escitalopram.

Authors:  William J Burke
Journal:  Expert Opin Investig Drugs       Date:  2002-10       Impact factor: 6.206

4.  Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.

Authors:  L L von Moltke; D J Greenblatt; G M Giancarlo; B W Granda; J S Harmatz; R I Shader
Journal:  Drug Metab Dispos       Date:  2001-08       Impact factor: 3.922

5.  Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups.

Authors:  Eric W Fish; Sara Faccidomo; Sandeep Gupta; Klaus A Miczek
Journal:  J Pharmacol Exp Ther       Date:  2003-10-30       Impact factor: 4.030

6.  Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen M Stahl; Ivan Gergel; Dayong Li
Journal:  J Clin Psychiatry       Date:  2003-11       Impact factor: 4.384

7.  Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

Authors:  Jack M Gorman; Andrew Korotzer; Guojin Su
Journal:  CNS Spectr       Date:  2002-04       Impact factor: 3.790

8.  Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison.

Authors:  Borwin Bandelow; Kirsten Behnke; Sergio Lenoir; G J Hendriks; Tunc Alkin; Claus Goebel; Cathryn M Clary
Journal:  J Clin Psychiatry       Date:  2004-03       Impact factor: 4.384

9.  The validity of a self-report questionnaire for diagnosing major depressive disorder.

Authors:  M Zimmerman; W Coryell
Journal:  Arch Gen Psychiatry       Date:  1988-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.